PMX

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Retrieved on: 
Tuesday, February 1, 2022
PMF, PCQ, New York Stock Exchange, Bank, Government, Risk, Contingent convertible bond, Loss, NAV, PML, PCK, Sale, Delinquent, Calendar, PIMCO, Mission statement, Clos, Environment, PNI, Leg, Government agency, PMX, Unitary state, News, Tax, PNF, PZC, Federal Reserve Board of Governors, Time, Investment, New, FDIC, Income, PDO, Record, Annual report, Life insurance, Security (finance), Fund

There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Key Points: 
  • There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.
  • The tax treatment and characterization of a Funds distributions may varysignificantly from time to time because of the varied nature of the Fundsinvestments.
  • As with any stock, the price of a Funds common shares will fluctuate with market conditions and other factors.
  • PIMCO Investments LLC, 1633 Broadway, New York, NY 10019, is a company of PIMCO.

Spectral Medical Announces U.S. FDA Approval of DIMI Trial Protocol Amendment

Retrieved on: 
Monday, January 31, 2022
CEO, Safety, Water quality, Risk, Patient, Toronto Stock Exchange, Clinical trial, Dialysis, Septic shock, Renal replacement therapy, Innovation, Adoption, TSX, Company, Health Canada, PMX, GLOBE, News, Sepsis, SAMI, FDA, RRT, U.S. FDA, Federal Food, Drug, and Cosmetic Act, EDT, Pharmaceutical industry, Medical device, Spectral

TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (Dialco) has received approval of a protocol amendment to its DIMI usability trial from the United States Federal Food and Drug Agency (FDA).

Key Points: 
  • TORONTO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT), today announced that its wholly-owned subsidiary, Dialco Medical Inc. (Dialco) has received approval of a protocol amendment to its DIMI usability trial from the United States Federal Food and Drug Agency (FDA).
  • This protocol amendment allows for both improved patient and clinical logistics flow in conducting the DIMI trial.
  • We worked closely with our clinical trial partners and vetted the modifications to our DIMI protocol with potential clinical trial sites.
  • We now believe we have an exceptional approved protocol for the DIMI trial and look forward to onboarding the clinical sites.

Spectral to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

Retrieved on: 
Friday, December 3, 2021
Patient, News, Renal replacement therapy, Septic shock, PMX, Spectral, Toronto Stock Exchange, EDT, Health Canada, Federal Food, Drug, and Cosmetic Act, TSX, Indian stock exchange, U.S. FDA, Risk, GLOBE, SAMI, FDA, RRT, Sepsis, Medical device, Pharmaceutical industry

TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to present at the SNN Network Canada Virtual Event taking place on December 7-9, 2021.

Key Points: 
  • TORONTO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Chris Seto, Chief Executive Officer of Spectral Medical, is scheduled to present at the SNN Network Canada Virtual Event taking place on December 7-9, 2021.
  • Mr. Seto is scheduled to present on Wednesday, December 8, 2021, at 9:00 A.M. Eastern Time.
  • SNN Network and Small Cap Discoveries, the leading Canadian MicroCap newsletter, have teamed up to highlight our neighbors to the North: Canada.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.

PIMCO Closed-End Funds Declare Monthly Common Share Distributions

Retrieved on: 
Wednesday, December 1, 2021
Income, PCI, PCQ, Investment, Risk, Contingent convertible bond, Government, Delinquent, Federal Reserve Board of Governors, Environment, Time, PMX, PNI, PNF, Clos, Calendar, PKO, Loss, FDIC, PIMCO, NAV, News, Sale, PML, New, PMF, PDI, Record, Government agency, New York Stock Exchange, PDO, Bank, Leg, Mission statement, PCK, Annual report, Unitary state, Tax, PZC, Life insurance, Security (finance)

There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.

Key Points: 
  • There can be no assurance that all distributions paid by these Funds will be exempt from federal income taxes or applicable state or local income taxes.
  • The tax treatment and characterization of a Funds distributions may varysignificantly from time to time because of the varied nature of the Fundsinvestments.
  • As with any stock, the price of a Funds common shares will fluctuate with market conditions and other factors.
  • PIMCO Investments LLC, 1633 Broadway, New York, NY 10019, is a company of PIMCO.

Spectral Medical Schedules Conference Call to Provide Clinical Update and Discuss Latest Developments

Retrieved on: 
Tuesday, November 30, 2021
Patient, News, Renal replacement therapy, Septic shock, PMX, Spectral, Toronto Stock Exchange, EDT, Health Canada, Federal Food, Drug, and Cosmetic Act, TSX, Telephone, U.S. FDA, Risk, GLOBE, SAMI, FDA, RRT, Sepsis, Pharmaceutical industry, Medical device

TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to provide a clinical update and discuss the latest business developments.

Key Points: 
  • TORONTO, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that it will host a conference call at 2:00 PM EST on Thursday, December 2, 2021, to provide a clinical update and discuss the latest business developments.
  • The conference call will be available via telephone by dialing toll free 877-407-0789 for U.S. callers or for international callers +1 201-689-8562.
  • A webcast of the call may be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72 or on the Companys Investor Events section of the website here .
  • Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin (PMX).

Spectral Medical Announces U.S. FDA Approval of Tigris Trial Protocol Amendment to Expand Inclusion Criteria

Retrieved on: 
Monday, November 29, 2021
Patient, Louisiana State University, Emergency medicine, Blood pressure, News, CEO, Renal replacement therapy, Septic shock, Heart rate, Degenerative disease, PMX, Company, Toronto Stock Exchange, Hospital, University of Michigan, Central venous pressure, EDT, Health Canada, Clinical trial, University of Arkansas, Federal Food, Drug, and Cosmetic Act, University, University of Pittsburgh School of Medicine, TSX, Organ dysfunction, COVID-19, Wilfrid Sellars, U.S. FDA, Risk, GLOBE, SAMI, Season, FDA, Mortality, Critical Care Medicine (journal), Associate professor, Cleveland Clinic, RRT, SOFA, Sepsis, MODS, COVID, Pharmaceutical industry, Medical device

TORONTO, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that the United States Federal Food and Drug Agency (“FDA”) has approved a protocol amendment to its Tigris trial allowing for the use of sequential organ failure assessment (“SOFA”) scoring as inclusion criteria into the study. Additionally, the Company announced five additional clinical sites to begin enrollment, including Louisiana State University, Cleveland Clinic, University of Arkansas, University of Michigan and Colorado Springs bringing the total number of participating sites to fifteen.

Key Points: 
  • Dr. John Kellum, Chief Medical Officer of Spectral, commented, We are very pleased with the FDA approval of our Tigris protocol amendment to allow the use of SOFA, which is an alternative scoring system used to quantify severity of illness.
  • I would expect this enrollment impact to be universal across other Tigris sites, and should greatly reduce the time needed to complete the trial.
  • Despite a challenging clinical environment due to COVID-19, Spectral has had success in adding new trial sites into the Tigris trial.
  • As a clinical site partner, we view the Tigris trial as a well designed study positioned for a positive outcome.

Spectral to Present at the Q4 Investor Summit on November 16th

Retrieved on: 
Monday, November 15, 2021
Toronto Stock Exchange, News, Septic shock, Renal replacement therapy, Health Canada, RRT, U.S. FDA, EDT, FDA, Spectral, Dialysis, Sepsis, TSX, Federal Food, Drug, and Cosmetic Act, Company, Patient, Risk, PMX, SAMI, Seto, Medical device

The Investor Summit is an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors.

Key Points: 
  • The Investor Summit is an exclusive, independent conference dedicated to connecting small cap and microcap companies with qualified investors.
  • The Q4 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors, family offices, and private wealth.
  • Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin ("PMX").
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.

Spectral to Present at the Benzinga Global Small Cap Conference on October 27, 2021

Retrieved on: 
Monday, October 25, 2021
Market capitalization, RRT, Patient, FDA, Sepsis, Toronto Stock Exchange, Health Canada, TSX, Risk, SAMI, U.S. FDA, Conference, PMX, EDT, Federal Food, Drug, and Cosmetic Act, News, Septic shock, GLOBE, Renal replacement therapy, Medical device, Pharmaceutical industry

TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Chris Seto, Chief Executive Officer of Spectral, will present at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021.

Key Points: 
  • TORONTO, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (Spectral or the Company) (TSX: EDT) and its wholly-owned subsidiary Dialco Medical Inc. (Dialco), today announced that Chris Seto, Chief Executive Officer of Spectral, will present at the Benzinga Global Small Cap Conference which is being held virtually on October 27-28, 2021.
  • Mr. Seto is scheduled to present on Wednesday, October 27th at 3:20 pm Eastern Time / 12:20 pm Pacific Time.
  • The Benzinga Global Small Cap Conference bridges the gap between Small Cap companies, investors, and traders.
  • Learn about small cap investing with clearly defined Educational Modules, take a look at a curated group of Small Cap investment opportunities, and connect with the global Small Cap audience in an intimate, virtual setting.

Spectral and Dialco Announce Dr. John Kellum to Be Featured as Keynote Lecturer at the 39th Vicenza Course on AKI and CRRT

Retrieved on: 
Wednesday, October 20, 2021
AKI, Renal replacement therapy, Risk, TSX, CRRT, RRT, News, Health Canada, Toronto Stock Exchange, EDT, Spectral, PMX, Hemofiltration, Sepsis, YouTube, FDA, SAMI, GLOBE, Patient, Federal Food, Drug, and Cosmetic Act, Acute kidney injury, U.S. FDA, Septic shock, Medical device, Animal

PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date.

Key Points: 
  • PMX has been approved for therapeutic use in Japan and Europe, and has been used safely and effectively on more than 300,000 patients to date.
  • Spectral, through its wholly owned subsidiary, Dialco Medical Inc., is also commercializing a new set of proprietary platforms addressing renal replacement therapy (RRT) across the dialysis spectrum.
  • While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect.
  • The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

Spectral Medical’s CMO Recognized as a World Expert in Sepsis; Supports World Sepsis Day and Sepsis Awareness Month

Retrieved on: 
Monday, September 13, 2021
Renal replacement therapy, Sepsis Alliance, FDA, Toronto Stock Exchange, Septic shock, U.S. FDA, Patient, PMX, Algorithm, Risk, PubMed, Spectral, SAMI, Federal Food, Drug, and Cosmetic Act, EDT, Health Canada, GLOBE, RRT, TSX, News, Method, Awareness, Birth control, Pharmaceutical industry, Medical device

TORONTO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and endotoxemic septic shock, as well as commercializing a new proprietary platform targeting the renal replacement therapy market through its wholly owned subsidiary Dialco Medical Inc. (“Dialco”), today announced that Dr. John Kellum, Spectral’s Chief Medical Officer, has been recognized as a World Expert in Sepsis by Expertscape.

Key Points: 
  • Additionally, 2021 is the 10th Anniversary of the Sepsis Alliance , the leading sepsis organization in the U.S. working to save lives and reduce suffering from sepsis.
  • Sepsis Alliance is a charitable organization run by a dedicated team who share a strong commitment to battling sepsis.
  • Spectral is honored to be a part of their journey of increasing awareness of sepsis to the public.
  • Spectral supports World Sepsis Day, which is September 13, 2021, as well as Sepsis Awareness Month, which is the month of September (#SAM2021).